Dai­ichi Sankyo sets new highs for As­traZeneca-part­nered can­cer drug En­her­tu

New ap­proved in­di­ca­tions and mas­sive year-over-year sales growth has Dai­ichi Sankyo eye­ing a year-end pop in sales for its As­traZeneca-part­nered can­cer drug En­her­tu.

The Japan­ese phar­ma on Mon­day upped its fore­cast for En­her­tu this year by more than $400 mil­lion, pro­ject­ing it could haul in about $1.3 bil­lion.

The in­crease in En­her­tu sales guid­ance fol­lows a land­mark da­ta drop and stand­ing ova­tion at AS­CO ear­li­er this sum­mer, as well as three la­bel ex­pan­sions as a sec­ond line treat­ment for HER2-pos­i­tive breast can­cer, in HER2-low metasta­t­ic breast can­cer, and as a sec­ond-line treat­ment for HER2-mu­tant metasta­t­ic non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.